163 related articles for article (PubMed ID: 30946706)
1. Uninterrupted non-vitamin K antagonist oral anticoagulants during implantation of cardiac implantable electronic devices in patients with atrial fibrillation.
Tsai CT; Liao JN; Chao TF; Lin YJ; Chang SL; Lo LW; Hu YF; Chung FP; Tuan TC; Chen SA
J Chin Med Assoc; 2019 Apr; 82(4):256-259. PubMed ID: 30946706
[TBL] [Abstract][Full Text] [Related]
2. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.
Black-Maier E; Kim S; Steinberg BA; Fonarow GC; Freeman JV; Kowey PR; Ansell J; Gersh BJ; Mahaffey KW; Naccarelli G; Hylek EM; Go AS; Peterson ED; Piccini JP;
Clin Cardiol; 2017 Sep; 40(9):746-751. PubMed ID: 28543401
[TBL] [Abstract][Full Text] [Related]
3. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Kosiuk J; Koutalas E; Doering M; Sommer P; Rolf S; Breithardt OA; Nedios S; Dinov B; Hindricks G; Richter S; Bollmann A
Europace; 2014 Jul; 16(7):1028-32. PubMed ID: 24489073
[TBL] [Abstract][Full Text] [Related]
4. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
5. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI).
Deharo JC; Sciaraffia E; Leclercq C; Amara W; Doering M; Bongiorni MG; Chen J; Dagres N; Estner H; Larsen TB; Johansen JB; Potpara TS; Proclemer A; Pison L; Brunet C; Blomström-Lundqvist C;
Europace; 2016 May; 18(5):778-84. PubMed ID: 27226497
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Jennings JM; Robichaux R; McElderry HT; Plumb VJ; Gunter A; Doppalapudi H; Osorio J; Yamada T; Kay GN
J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1125-9. PubMed ID: 23889767
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
11. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).
Birnie DH; Healey JS; Wells GA; Ayala-Paredes F; Coutu B; Sumner GL; Becker G; Verma A; Philippon F; Kalfon E; Eikelboom J; Sandhu RK; Nery PB; Lellouche N; Connolly SJ; Sapp J; Essebag V
Eur Heart J; 2018 Nov; 39(44):3973-3979. PubMed ID: 30462279
[TBL] [Abstract][Full Text] [Related]
12. Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial.
Ricciardi D; Creta A; Colaiori I; Scordino D; Ragni L; Picarelli F; Calabrese V; Providência R; Ioannou A; Di Sciascio G
Pacing Clin Electrophysiol; 2018 Nov; 41(11):1476-1480. PubMed ID: 30132926
[TBL] [Abstract][Full Text] [Related]
13. Pocket haematoma after cardiac electronic device implantation in patients receiving antiplatelet and anticoagulant treatment: a single-centre experience.
Demir GG; Guler GB; Guler E; Güneş H; Kizilirmak F; Karaca İO; Omaygenç MO; Çakal B; Olgun E; Savur U; Ibisoglu E; Barutçu I; Kiliçaslan F
Acta Cardiol; 2017 Feb; 72(1):47-52. PubMed ID: 28597740
[TBL] [Abstract][Full Text] [Related]
14. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Bouillon K; Bertrand M; Maura G; Blotière PO; Ricordeau P; Zureik M
Lancet Haematol; 2015 Apr; 2(4):e150-9. PubMed ID: 26687957
[TBL] [Abstract][Full Text] [Related]
15. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
16. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal?
Di Cori A; Lilli A; Zucchelli G; Zaca V
Expert Rev Cardiovasc Ther; 2018 Mar; 16(3):175-181. PubMed ID: 29431527
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
[TBL] [Abstract][Full Text] [Related]
18. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
[TBL] [Abstract][Full Text] [Related]
19. Periprocedural Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation Without Discontinuation of a Vitamin K Antagonist and Direct Oral Anticoagulants.
Kojima T; Fujiu K; Fukuma N; Matsunaga H; Oshima T; Matsuda J; Matsubara T; Shimizu Y; Oguri G; Hasumi E; Morita H; Komuro I
Circ J; 2018 May; 82(6):1552-1557. PubMed ID: 29657252
[TBL] [Abstract][Full Text] [Related]
20. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
